SRX Global sells 3,579 Series C preferred shares in private placement valued at $2.86 million
SRXH•Private placement details
SRX Global entered a private placement on Aug. 27, 2026, issuing 3,579 shares of Series C convertible preferred stock.
Investors paid $2.86 million via assignment of CERO Therapeutics Convertible Grid Promissory Notes with $2.81 million principal.
Terms of the Series C preferred stock
The Series C preferred carries a $1,000 stated value per share.
The security ranks senior to common stock, pari passu with Series A and Series B preferred stock.
Holders receive dividends on an as-converted basis, matching any dividends paid on common stock.
